Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused by platinum agents and PARP inhibitors. Triple-negative breast cancers (TNBCs) harbor subpopulations with BRCA1/2 mutations, hypothesized to be especially platinum-sensitive. Cancers in putative ‘BRCAness’ subgroups—tumors with BRCA1 methylation; low levels of BRCA1 mRNA (BRCA1 mRNA-low); or mutational signatures for HR deficiency and those with basal phenotypes—may also be sensitive to platinum. We assessed the efficacy of carboplatin and another mechanistically distinct therapy, docetaxel, in a phase 3 trial in subjects with unselected advanced TNBC. A prespecified protocol enabled biomarker–treatment interaction analyses in gBRCA-BC and BRCAness subgroups. The primary endpoint was objective response rate (ORR). In the unselected population (376 subjects; 188 carboplatin, 188 docetaxel), carboplatin was not more active than docetaxel (ORR, 31.4% versus 34.0%, respectively; P = 0.66). In contrast, in subjects with gBRCA-BC, carboplatin had double the ORR of docetaxel (68% versus 33%, respectively; biomarker, treatment interaction P = 0.01). Such benefit was not observed for subjects with BRCA1 methylation, BRCA1 mRNA-low tumors or a high score in a Myriad HRD assay. Significant interaction between treatment and the basal-like subtype was driven by high docetaxel response in the nonbasal subgroup. We conclude that patients with advanced TNBC benefit from characterization of BRCA1/2 mutations, but not BRCA1 methylation or Myriad HRD analyses, to inform choices on platinum-based chemotherapy. Additionally, gene expression analysis of basal-like cancers may also influence treatment selection.The phase 3 TNT Trial in subjects with triple-negative breast cancer supports the superiority of carboplatin over docetaxel in BRCA1/2-mutated tumors and a greater response to taxanes in the nonbasal subtype.

[1]  E. Mardis,et al.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.

[2]  R. L. Baldwin,et al.  BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. , 2006, Gynecologic oncology.

[3]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[4]  W. Symmans,et al.  Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC). , 2017 .

[5]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W. Gradishar,et al.  Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Z. Szallasi,et al.  Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.

[8]  A. Ashworth,et al.  Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[9]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[10]  J. Ragaz,et al.  Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[11]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[13]  R. Greil,et al.  Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[15]  Z. Szallasi,et al.  Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[16]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[17]  Harold L. Moses,et al.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection , 2016, PloS one.

[18]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[19]  R. L. Baldwin,et al.  BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. , 2000, Cancer research.

[20]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[21]  J. Ott,et al.  The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia , 2005, Nature Genetics.

[22]  A. Ashworth,et al.  Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. , 2015, Cancer discovery.

[23]  P. Kristel,et al.  Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. , 2016, Journal of the National Cancer Institute.

[24]  E. Winer,et al.  TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[26]  G. Sledge,et al.  Cisplatin as first-line therapy for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Couch,et al.  Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer , 2014, Journal of the National Cancer Institute.

[28]  Alexander Gutin,et al.  Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes , 2014, Breast Cancer Research.

[29]  E. Winer,et al.  Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[31]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[32]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[33]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[34]  S. Narod,et al.  Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Rezai,et al.  Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. , 2015 .

[36]  A. D’Andrea,et al.  Molecular pathogenesis of Fanconi anemia: recent progress. , 2006, Blood.

[37]  C. Perou,et al.  Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Berry,et al.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Venkitaraman.  Tracing the network connecting brca and fanconi anaemia proteins , 2004, Nature Reviews Cancer.

[40]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[41]  Patrick Royston,et al.  Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome , 2013, BMC Medical Research Methodology.

[42]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[43]  Miguel Martín,et al.  Platinum compounds in the treatment of advanced breast cancer. , 2001, Clinical breast cancer.

[44]  Joanna R. Morris,et al.  BRCA1 methylation: a significant role in tumour development? , 2002, Seminars in cancer biology.

[45]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[46]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[47]  Jeff Myers,et al.  Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.